CompBrief BY VELARION

Companies Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics CEO salary & total pay, FY2025: $713K

Brainstorm Cell Therapeutics (BCLI) CEO salary, fiscal 2025: Chaim Lebovits was paid a salary of $291,667 and $713,341 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Brainstorm Cell Therapeutics Inc’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Chaim Lebovits's complete compensation dossier

A PDF and a CSV sent to your email: Chaim Lebovits's pay in every fiscal year Brainstorm Cell Therapeutics Inc reported it, line by line, with Chaim Lebovits's equity grants and Brainstorm Cell Therapeutics Inc's disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$713,341CEO Chaim Lebovits · source
Say-on-pay support89.87%Latest vote · source

CEO pay, last three years

  • $1,128,795FY2023
  • $750,303FY2024
  • $713,341FY2025

CEO total pay was $713,341 in fiscal 2025, down from $750,303 in fiscal 2024.

FY2025: salary $291,667 · bonus $0 · stock awards $256,800 · option awards $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Brainstorm Cell Therapeutics Inc in fiscal 2025?
As disclosed, Chaim Lebovits (Chief Executive Officer & President) was the highest-paid executive at Brainstorm Cell Therapeutics Inc in fiscal 2025, with total compensation of $713,341.
How did shareholders vote on Brainstorm Cell Therapeutics Inc's executive compensation?
As disclosed, 89.87% of shareholders supported Brainstorm Cell Therapeutics Inc's executive compensation in the latest say-on-pay vote.
How much does Brainstorm Cell Therapeutics Inc spend in total on board compensation for fiscal 2025?
As disclosed, Brainstorm Cell Therapeutics Inc reported total board compensation of $253,945 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Chaim Lebovits$291,667$0$256,800$0$0$0$164,874$713,341
Chief Executive Officer & President
Uri Yablonka123,5650128,40000076,348328,313
Executive Vice President, Chief Business Officer, Secretary and Director

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Chaim Lebovits$713,341$750,303$1,128,795↓ −36,962
Uri Yablonka328,313266,138247,055↑ +62,175

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation structure for executives is primarily based on base salary and discretionary cash bonuses, with long-term incentives provided through stock options and restricted stock awards that vest over time to align executive interests with long-term shareholder value.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingfalse
Anti-pledgingfalse
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Chaim LebovitsRSU—60,000—$33,000
Chaim LebovitsRSU—10,173—5,595
Chaim LebovitsRSU—520—286
Chaim LebovitsRSU—1,039—571
DagherOption3,0002,33325.95—
DagherRSU—7,258—3,992
DagherRSU—25,000—13,750
Uri YablonkaRSU—40,000—22,000
Uri YablonkaRSU—3,647—2,006
Uri YablonkaOption889—11.25—
Uri YablonkaOption889—11.25—
Uri YablonkaOption889—11.25—
Uri YablonkaOption889—11.25—
Uri YablonkaOption889—11.25—
Uri YablonkaOption889—11.25—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Dr. Jacob Frenkel$0$85,600$0——$85,600
Dr. Irit ArbelIndependent · Audit · GNC (Chair)065,6250——65,625
Dr. Anthony PolverinoGNC051,3600——51,360
Dr. Menghisteab BairuIndependent · Audit051,3600——51,360
Nir NaorIndependent · Audit (Chair) · GNC000———

Board fee structure and ownership guideline

Annual cash retainer$30,000
Annual equity retainer$444
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)222 / 222
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$0
Equity awards (grant-date value)$253,945
All other compensation$0
Total cost of the board$253,945

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Brainstorm Cell Therapeutics as a peer

Companies that benchmark against BCLI

No companies currently name BCLI as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Brainstorm Cell Therapeutics Inc2025Chaim Lebovits$291,667$256,800$0$0$713,341

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-25—————
20242024-09-1623,439,7242,640,8613,262,78289.87%Passed
20232023-12-18—————
20212021-12-147,594,234981,37494,59688.56%Passed
20202020-11-10—————
20192019-12-11—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20252025-06-25—a
20242024-09-1689.87%b
20232023-12-18—c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Approval, on a Non-binding Advisory Basis, of the Compensation of the Company's Named Executive Officers (Proposal No. 7) The approval of Proposal No. 7 requires the affirmative vote of a majority of the votes cast by the stockholders present at the virtual Meeting or represented by proxy and entitled to vote on the matter. || Abstentions: Abstentions and broker non-votes will not be counted as votes cast or voted on Proposal No. 7.”.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dr. Jacob FrenkelDirector2026-07-24A100,000$0$0CommonForm 4 ↗
Peter Joe PittsDirector2026-07-24A900,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (15 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Chaim Lebovits. 10-K, filed 2026-03-31. Section “Executive Compensation”. As printed: 713,341. View filing ↗
  • Section 01, Uri Yablonka. 10-K, filed 2026-03-31. Section “Executive Compensation”. As printed: 328,313. View filing ↗
  • Section 08, Dr. Jacob Frenkel. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 85,600. View filing ↗
  • Section 08, Dr. Irit Arbel. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 65,625. View filing ↗
  • Section 08, Dr. Anthony Polverino. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 51,360. View filing ↗
  • Section 08, Dr. Menghisteab Bairu. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: 51,360. View filing ↗
  • Section 08, Nir Naor. DEF 14A, filed 2026-03-31. Section “Director Compensation”. As printed: —. View filing ↗
  • Section 02, Dr. Jacob Frenkel 2026-07-24. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Peter Joe Pitts 2026-07-24. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-09-16. Item 5.07 · say-on-pay result. As reported: 89.87% (votes for as printed: 23,439,724). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-12-20. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 0 + equity 253,945 + all other 0 = 253,945, summed across the director compensation table rows.
  • Brainstorm Cell Therapeutics Inc (subject), Section 10b CEO total. 10-K, filed 2026-03-31. CEO total compensation as printed in Brainstorm Cell Therapeutics Inc's own proxy. As printed: 713,341. View filing ↗
Get the full report — $299